FNDC5 and metabolic syndrome: The pro-osteogenic effect of irisin is particularly significant in states of bone destruction caused by metabolic syndromes such as diabetes, where irisin treatment enhances cell viability and osteogenic effects, mitigating the negative impact of advanced glycation end-products (AGEs) on adipose stem cells.